First preservative-free multidose dispenser chosen for prescription eye treatment

Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is now available for the first time for patients in the US prescription market using Allergan’s Restasis MultiDose (Cyclosporine Ophthalmic Emulsion) 0.05%.

This approval and launch makes the Ophthalmic Squeeze Dispenser the first and only US FDA approved multidose delivery system to handle prescription eye treatment formulation without any preservatives.

Both companies are working closely together to ensure patient safety is improved and that dosing accuracy is achieved while maintaining product integrity. “Our Ophthalmic Squeeze Dispenser technology has been a great success for our customers,” explained Salim Hafir, president of Aptar Pharma. “The proven and unrivalled microbiological safety, combined with precise and reproducible drop ejection allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the FDA.”

Dry eye is a common problem and can require prolonged treatment, if not for the rest of the patient’s life, therefore, a preservative-free solution can assist in patient comfort and adherence to therapy. It has been well proven that preservatives can cause unpleasant and potentially serious side effects.

Aptar Pharma (Crystal Lake, Illinois, USA) is a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer healthcare, injectables, food and beverage markets.